|
Originally published In Press as doi:10.1074/jbc.M205658200 on July 22, 2002
J. Biol. Chem., Vol. 277, Issue 40, 37479-37486, October 4, 2002
Frizzled-9 Is Activated by Wnt-2 and Functions in Wnt/ -Catenin
Signaling*
Takatoshi
Karasawa §,
Hisayuki
Yokokura ,
Jan
Kitajewski¶, and
Paul J.
Lombroso
From the Child Study Center and
§ Interdepartmental Neuroscience Program, Yale University
School of Medicine, New Haven, Connecticut 06520 and the
¶ Departments of Pathology and Obstetrics/Gynecology, Columbia
University, New York, New York 10032
Received for publication, June 7, 2002, and in revised form, July 15, 2002
 |
ABSTRACT |
Frizzled has been known to function as a Wnt
receptor. Although there have been a number of mammalian Frizzled
members identified, their binding specificities with Wnt and functions
in mammalian cells have been poorly understood. Here, we demonstrate
that rat Frizzled-9 (Rfz9) functions in Wnt/ -catenin signaling in
293T cells. Rfz9 overexpression induces the hyperphosphorylation and relocalization of mouse Dishevelled-1 (Dvl-1) from the cytoplasm to the
cell membrane and the accumulation of cytosolic -catenin. Transfections of Rfz9 with each of several Wnt members show that only
Wnt-2 activates Rfz9 in T cell factor (TCF)-dependent
transcription. Deletion mutant analysis determines that there is a
difference in Rfz9 C-terminal residues required for the modifications
of Dvl-1 and those required for the inductions of -catenin
stabilization and TCF transactivation. Deletion of the Wnt-binding
domain does not abolish Rfz9 activity completely, although it causes
the inactivation of Wnt-2-dependent TCF transcription. Rfz9
also relocalizes Axin from the cytoplasm to the plasma membrane in the
presence of Dvl-1, suggesting that one of the consequences of Dvl-1
relocalization by Rfz9 is to bring Axin to the cell membrane.
 |
INTRODUCTION |
Wnt proteins are a family of ligand molecules that play major
roles in development, such as embryogenesis, cell polarity generation, and cell fate specification (1, 2). Studies on Drosophila have identified a number of genes that are involved in the Wnt signaling, including Frizzled as a Wnt receptor (3). Recent studies
have characterized the molecular mechanisms of the signaling pathway
that involves -catenin. In the absence of the Wnt signaling, phosphorylation by glycogen synthase kinase 3 causes the cytoplasmic -catenin to be ubiquitinated and degraded through a mechanism that
requires adenomatous polyposis coli and Axin (4, 5). Wnt binds and
activates the co-receptors Frizzled and the low density
lipoprotein-related proteins 5 and 6 (LRP5/6)1 (6).
Wnt-dependent activation of LRP5/6 recruits Axin to the membrane, where Axin is destabilized (7). Frizzled relocalizes Dishevelled from the cytoplasm to the cell membrane, and the
membrane-associated Dishevelled is hyperphosphorylated (8, 9).
Dishevelled binds to a protein complex containing Axin, glycogen
synthase kinase 3 , and adenomatous polyposis coli, which leads to
suppression of glycogen synthase kinase 3 activity, resulting in
stabilization and accumulation of cytoplasmic -catenin (10-15). In
the nucleus, accumulated -catenin binds to members of the T cell
factor/lymphoid enhancer factor (TCF/LEF) transcription factor family
(16, 17) and induces transcription of target genes (18-21).
Frizzled family proteins are seven transmembrane-spanning receptors
that are activated by Wnt. The N-terminal extracellular cysteine-rich
domain (CRD) has been identified as the Wnt-binding domain (22, 23).
The C-terminal tail is the most variable part among Frizzled homologs
(24). Using assays in Xenopus embryos, rat Frizzled-1 (Rfz1)
has been shown to relocalize Xenopus Dishevelled (Xdsh) and
induce expression of -catenin-responsive genes, Xnr-3 and
Siamois (25). Human Frizzled-5 (Hfz5) can be activated by Wnt-5a and induce the secondary axis formation (26). Studies in
mammalian cells have revealed that human Frizzled-1 (Hfz1) is activated
by several Wnt homologs in TCF reporter assays in 293T cells (27).
Mouse Frizzled-8 (Mfz8) can also be activated by Wnt-1 in a similar
assay (28). Direct interactions between Wnt and mammalian Frizzled were
confirmed by the demonstrations that Drosophila Wingless
(Wg) and Xenopus Wnt-8 (Xwnt-8) can bind to several mouse
Frizzled members in 293 and COS cells (3, 22).
Despite the fact that a number of mammalian Wnt and Frizzled members
have been identified, there has been little characterization of
Wnt-Frizzled binding specificities. In fact, only a few Frizzled members have been shown to function in Wnt/ -catenin signaling in
mammalian cells. In the present study, we characterize a recently identified Frizzled family member, Frizzled-9, in Wnt/ -catenin signaling. Frizzled-9 is highly expressed in the brain, and its gene is
one of several genes that are deleted in a developmental disorder,
Williams syndrome (29, 30). The gene deletion is thought to contribute
to the neurological symptoms of Williams syndrome (29, 30). We
demonstrate that rat Frizzled-9 (Rfz9) functions in Wnt/ -catenin
signaling in mammalian cells and that Rfz9 can act as a receptor for
Wnt-2. Importantly, there is a difference in the Rfz9 C-terminal
residues required for the inductions of mouse Dishevelled-1 (Dvl-1)
modifications and those required for -catenin accumulation and TCF
transactivation. Deletion of a large part of the CRD retains the Rfz9
activity, although it causes the inactivation of
Wnt-2-dependent TCF transcription. Rfz9 also relocalizes
Axin to the cell membrane in Dvl-1-dependent manner, and
the Rfz9 mutants that can translocate Dvl-1 also relocalize Axin,
suggesting that one of the consequences of Dvl-1 relocalization by Rfz9
is to bring Axin to the cell membrane.
 |
EXPERIMENTAL PROCEDURES |
Rfz9 Cloning--
Based on the DNA sequences of human and mouse
Frizzled-9 (Hfz9 and Mfz9, respectively), PCR primers were designed to
isolate an 800-bp fragment at the 3' end of the Rfz9 coding
region. The DNA fragment generated by PCR was used as the probe to
screen a rat cortex cDNA library cloned in the Lambda ZAP II vector
(Stratagene). After three rounds of selection by hybridization,
pBluescript phagemids were excised from the positive clones and sequenced.
Plasmid Constructions--
Rfz9 wild-type, Rfz9-Myc, Rfz9 C5,
C15, C26, and C38 expression constructs were generated from
the cloned full-length Rfz9 cDNA by PCR amplification and/or
restriction digestion and subcloning into pCMV-Tag5B or pCMV-Tag5C
(Stratagene). Rfz9 N and Rfz9 N-Myc were generated by the removal
of a smaller fragment and self-ligation of a larger fragment from
restriction digestion of the Rfz9 wild-type and Rfz9-Myc constructs,
respectively. Green fluorescent protein (GFP)-tagged and V5-tagged
Dvl-1 (Dvl-1-GFP and Dvl-1-V5) were generated by PCR amplification of
Dvl-1 (a gift from D. J. Sussman) and subcloning into pEGFP-N2
(CLONTECH) and pcDNA3.1/V5/His (Invitrogen), respectively. To remove the His6 epitope from
pcDNA3.1/V5/His in the Dvl-1-V5 construct, Dvl-1-V5 was amplified
by PCR and subcloned into pEGFP-N2. GFP-tagged Axin (Axin-GFP) was
generated by PCR amplification of amino acids 125-956 (form 1) of Axin
(a gift from F. Costantini) and subcloned into pEGFP-N2.
Cell Culture and Transfection--
293T cells were maintained in
Dulbecco's modified Eagle's medium supplemented with 10% fetal
bovine serum, 5% sodium pyruvate, and 100 units/ml
penicillin/streptomycin. Cells were transfected using
LipofectAMINE 2000 (Invitrogen) for immunofluorescence experiments and
using GeneJammer transfection reagent (Stratagene) for the other
transfection experiments. Except for immunofluorescence, all
transfected cells were assayed 48 h after transfection.
Immunofluorescence--
For Dvl-1-GFP localization,
transfections were performed in 35-mm dish cultures with Dvl-1-GFP (1.0 µg) together with either an Rfz9 construct or vector control (2.2 µg). For Axin-GFP localization, transfections were performed with
Axin-GFP (1.0 µg) together with either Rfz9 or vector (2.2 µg). For
Axin-GFP localization in the presence of Dvl-1-V5, transfections were
performed with Axin-GFP (0.4 µg), Dvl-1-V5 (0.8 µg), and an Rfz9
construct or vector (2.0 µg). 24 h after transfection, cells
were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS)
and permeabilized with 0.2% Triton X-100 in PBS. After incubation with
monoclonal anti-Myc antibody (9E10) or anti-V5 antibody (Invitrogen),
immunoreactivity was detected by Cy3-conjugated anti-mouse secondary
antibody (Jackson ImmunoResearch Laboratories). Images were obtained
using a confocal laser-scanning fluorescence microscope
(Carl-Zeiss).
Alkaline Phosphatase Treatment--
Cells in 6-well plates were
transfected with 0.3 µg of Dvl-1-V5 and 0.7 µg of Rfz9 or vector
for each well. The cells were washed twice with ice-cold PBS,
scraped, and centrifuged in lysis buffer (50 mM Tris, pH
7.4, 1% Triton X-100, 150 mM NaCl, 5 mM EGTA,
5 mM EDTA, 50 mM NaF, 1 mM
Na3VO4) containing protease inhibitors at
4 °C for 20 min to remove cell debris. Cell lysate was precleared with 20 µl of protein A-agarose at 4 °C for 1 h. The sample
was spun down to remove the pellet, and 1 µl of anti-V5 antibody and 20 µl of protein A-agarose were added and incubated at 4 °C
overnight. The mixture was washed with 500 µl of lysis buffer twice,
90 µl of phosphatase buffer and 10 µl (10 units) of alkaline
phosphatase (Roche Molecular Biochemicals) were added, and the reaction
mixture was incubated at 37 °C for 2 h. The sample was washed
with lysis buffer twice and resuspended in 30 µl of SDS sample buffer
and analyzed by SDS-polyacrylamide gel electrophoresis and immunoblot.
Cell Fractionation and Immunoblot--
Cell fractionation was
performed as described (31). Briefly, cells transfected with 2 µg of
DNA in 60-mm dishes were washed twice with ice-cold PBS. The cells were
scraped and disrupted by 10 strokes with a Dounce homogenizer in
hypotonic buffer (10 mM -glycerophosphate, pH 7.4, 1 mM MgCl2, 2 mM EGTA, 1 mM dithiothreitol) containing protease inhibitors (200 µl/dish). The homogenate was loaded onto 200 µl of 2 M
sucrose in hypotonic buffer and centrifuged at 15,000 × g for 30 min to pellet intact cells and nuclei. The supernatant from above the sucrose cushion was centrifuged at 100,000 × g for 30 min, and the resultant supernatant
was designated as the cytosolic fraction. The pellet was solubilized in
hypotonic buffer containing 0.5% Triton X-100 and 0.1% sodium
deoxycholate and was designated as the membrane fraction. For Dvl-1-V5,
Rfz9-Myc, or Rfz9 mutant detection in immunoblot, transfected cells in
a 6-well plate were scraped and centrifuged in lysis buffer (50 mM Tris, pH 7.4, 1.2% Nonidet P-40, 150 mM
NaCl, 5 mM EGTA, 5 mM EDTA, 0.1% SDS)
containing protease inhibitors at 4 °C for 20 min to remove cell
debris. Protein concentrations were determined by the BCA assay
(Pierce). Samples were electrophoresed in SDS-polyacrylamide gel and
transferred onto nitrocellulose membranes. The membranes were blocked
with 5% skim milk in PBS with 0.1% Tween 20 and probed with anti-Myc,
anti-V5, anti- -catenin (Transduction Laboratories), or anti-actin
antibody (Sigma). Peroxidase-conjugated secondary antibodies against
rabbit IgG and mouse IgG (Jackson ImmunoResearch Laboratories) were
used and visualized by enhanced chemiluminescence.
Luciferase Assay--
Transfections were performed in 6-well
plate cultures with 0.3 µg of an Rfz9 construct or vector, 0.6 µg
of a Wnt-HA (32) or vector, 0.05 µg of a reporter construct TOPFLASH
or FOPFLASH (gifts from G. Watanabe) (33), and 0.05 µg of the
-galactosidase expression construct pcDNA3.1/LacZ (Invitrogen).
After 48 h, proteins were extracted using the reporter
lysis buffer of Luciferase Assay System (Promega), and a luminometer
(Bio-Rad) was used to measure luciferase activity. -galactosidase
activity was measured to normalize transfection efficiency. All
experiments were performed in triplicate unless indicated otherwise.
 |
RESULTS |
Cloning of Rfz9--
We screened a rat cortex cDNA library to
clone Rfz9, and four positive clones were identified. Overlapping
regions of their sequences match completely, and one of them has a
full-length cDNA. The sequence encodes a protein of 592 amino
acids, which is identical to Mfz9 except for a threonine at position
490 that is substituted with an alanine. The corresponding position in Hfz9 is also alanine. The coding region is 96 and 87% identical at the
DNA level to Mfz9 and Hfz9, respectively. As is the feature of other
Frizzled family members, Rfz9 contains an extracellular cysteine-rich domain (CRD) at the N terminus, seven putative
transmembrane domains, and a cytoplasmic tail at the C terminus.
Rfz9 Functions in Wnt/ -Catenin Signaling--
Most Frizzled
members that activate Wnt/ -catenin signaling relocalize Dishevelled
from the cytoplasm to the cell membrane (34). Thus, we tested whether
Rfz9 can also relocalize Dishevelled, using a GFP fusion of Dvl-1
(Dvl-1-GFP). In 293T cells, Dvl-1-GFP has a cytoplasmic speckled
expression pattern (Fig. 1A,
a-c), similar to that found in Xenopus embryos
injected with Xdsh (25, 35) or Drosophila Dishevelled (Ddsh)
(8). When Dvl-1-GFP was coexpressed with Rfz9-Myc, all cells that
express both proteins show plasma membrane localization of Dvl-1-GFP
(Fig. 1A, d-f), as has been reported with Xdsh
co-injected with Rfz1 or Xenopus Frizzled homologs (25, 35)
or Ddsh co-injected with Drosophila Frizzled homologs into
Xenopus embryos (8). Rfz9-Myc localized primarily to the
cell membrane, although some intracellular expression was seen, most
likely reflecting retention in the endoplasmic reticulum.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 1.
Rfz9 functions in
Wnt/ -catenin signaling. Dvl-1 is
relocalized by Rfz9 (A). Dvl-1-GFP was cotransfected with
vector (a-c) or with Rfz9-Myc (d-f). The
Myc-tagged Rfz9 was detected with anti-Myc antibody in
image d but not in image a. Dvl-1-GFP was
directly detected by fluorescence (b and e).
Merged image c is from a and b, and
merged image f is from d and e. Dvl-1
is hyperphosphorylated by Rfz9 (B). Upper panel,
Dvl-1-V5 (0.3 µg) was cotransfected with an indicated amount of Rfz9
and vector to make up a total of 1.0 µg of DNA. The proteins were
detected with anti-V5 antibody. Lower panel, Dvl-1-V5 was
cotransfected with Rfz9 or vector, and cells were immunoprecipitated
with anti-V5 antibody followed by alkaline phosphatase treatment. The
proteins were detected with anti-V5 antibody. Rfz9 induces the
accumulation of cytosolic -catenin (C). Cells transfected
with Rfz9 or vector were fractionated. The proteins were detected with
anti- -catenin and anti-actin antibodies. Rfz9 activates TCF
transcription (D). Cells were transfected with 0.3 µg of
Rfz9 (right bar) or vector (left bar), 0.05 µg
of TOPFLASH, 0.05 µg of pcDNA3.1/LacZ, and 0.6 µg of vector.
The relative values represent the means from six independent
experiments.
|
|
Dishevelled relocalization by Frizzled correlates with the
hyperphosphorylation of Dishevelled (35). When V5-tagged Dvl-1 (Dvl-1-V5) was expressed alone, two bands were detected by Western blot
with similar band intensities (Fig. 1B, upper
panel). The slower migrating (upper) band most likely reflects a
mobility shift caused by phosphorylation as has been reported
previously (36). With Rfz9 coexpression, the faster migrating
(lower) band decreases, and a band that migrates even slower
than the upper band appears in a dose-dependent manner of
the transfected Rfz9 plasmid. Alkaline phosphatase treatment of
Dvl-1-V5 shifted all Dvl-1-V5 to the lower band, confirming that the
upper bands were indeed caused by phosphorylation (Fig. 1B,
lower panel).
Xenopus embryo studies have shown that some Frizzled
proteins can activate Wnt/ -catenin signaling without ectopic Wnt
expression (25, 37, 38). The effect of Rfz9 on -catenin
stabilization was examined by cell fractionation to separate cytosol
and membrane fractions of 293T cells since most -catenin associated
with the cell membrane does not function in Wnt/ -catenin signaling.
When Rfz9 was expressed, -catenin accumulation in the cytosolic
fraction was significantly higher than vector-transfected cells (Fig.
1C). The membrane -catenin level was not affected by Rfz9
expression. To further confirm that Rfz9 activates Wnt/ -catenin
signaling, luciferase assays were performed using a reporter construct,
TOPFLASH, which contains multimeric TCF-binding sites upstream
of c-fos promotor driving luciferase expression (33). Rfz9
increased TCF transcription activity ~2-fold as compared with
vector-transfected cells (Fig. 1D).
Wnt-2 Can Activate Rfz9-dependent TCF
Transcription--
To identify possible physiological ligands for
Rfz9, a number of Wnt homologs were tested for their ability to enhance
Rfz9-dependent TCF transcription. When Rfz9 was coexpressed
with each of the Wnt proteins, a 10-fold increase of TCF activity was
observed in the cells cotransfected with Wnt-2 as compared with Rfz9
alone (Fig. 2A). This was a
striking observation as all other Wnt, including Wnt-1, -3, -3a, -4, -5a, -5b, -7a, and -7b, tested with Rfz9 showed no significant increase
of TCF activity, and Wnt-2 alone did not induce TCF activity higher
than vector transfection (Fig. 2A and data not shown). The
differences in luciferase activity could not be accounted for by
differences in Wnt expression levels since all of these HA-tagged Wnt
constructs expressed comparable levels of proteins as reported
previously (data not shown, and Refs. 27 and 32). Luciferase activity
was not significantly increased with FOPFLASH, the reporter plasmid
with mutated TCF-binding sites, confirming that Wnt-2 and Rfz9
specifically activates TCF (Fig. 2B).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 2.
Rfz9 is activated by Wnt-2. Cells were
transfected with 0.3 µg of Rfz9 or vector, 0.6 µg of a Wnt-HA
(Wnt-1, Wnt-2, Wnt-3, or Wnt-3a) or vector, 0.05 µg of TOPFLASH, and
0.05 µg of pcDNA3.1/LacZ (A). The relative values
represent the means from three independent experiments. Cells were
transfected with 0.3 µg of Rfz9 or vector, 0.6 µg of Wnt-2 or
vector, 0.05 µg of TOPFLASH or FOPFLASH, and 0.05 µg of
pcDNA3.1/LacZ (B). The relative values represent the
means from three independent experiments. Cells were transfected with 2 µg of Wnt-2, Rfz9, or vector and fractionated (C). For
coexpression, Wnt-2 (1.3 µg) and Rfz9 (0.65 µg) were cotransfected
and fractionated. Cytosolic fractions were blotted, and the proteins
were detected with anti- -catenin and anti-actin antibodies.
|
|
To confirm that there is a correlation between TCF activity and
-catenin accumulation induced by Wnt-2 and Rfz9, cytosolic -catenin levels were analyzed in the cotransfected cells. As expected, they showed higher -catenin levels than those that expressed Wnt-2 or Rfz9 alone (Fig. 2C). Although the
synergy between Wnt-2 and Rfz9 is not very evident with the -catenin levels, it is most likely due to the presence of the cells that were
untransfected and those transfected with Wnt-2 or Rfz9 alone in the
sample. In the TCF reporter assays, on the other hand, most cells
transfected with the reporter gene were also transfected with Wnt-2 and
Rfz9.
There is an apparent discrepancy between the -catenin accumulation
and TCF activity data for the cells transfected with Wnt-2 and Rfz9
separately (Fig. 2, A and C). Whereas Wnt-2
accumulated -catenin more than Rfz9, the TCF assay results show that
the cells transfected with Wnt-2 did not show any TCF activity, as opposed to Rfz9 with 2-fold increase when compared with vector control.
Although it is not clear why Wnt-2 alone can accumulate -catenin but
cannot activate TCF activity, one possible explanation is that a major
pool of cytosolic -catenin is bound to -catenin inhibitory
proteins such as Duplin and ICAT (39, 40), preventing -catenin from
activating TCF, and Rfz9 but not Wnt-2 alone releases this inhibition.
Most of the Rfz9 C-terminal Tail Is Dispensable for Dvl-1
Relocalization and Hyperphosphorylation--
To identify Rfz9 domains
that are responsible for Wnt/ -catenin signaling activation, a number
of Rfz9 C-terminal deletion mutants (Rfz9 C) were generated (Fig.
3A). They were generated as
Myc tag fusion proteins so that the expression of the mutants could be
confirmed. These constructs expressed comparable levels of proteins
(Fig. 3B). The lower one of the two bands that were detected
for Rfz9 C26 may be a degradation product. In Rfz9 N-Myc, the band
that appears at a similar size to the other mutants may possibly be
endogenous c-Myc, which is also detected faintly in vector-transfected
cells (Fig. 3B). All the Rfz9 mutants were localized to the
cell membrane, although there was some endoplasmic reticulum expression
detected (Fig. 4A,
g-i, for Rfz9 C38 as the representation of the Rfz9 C
mutants).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 3.
A, schematic representation of
Rfz9 wild type and mutants. All Rfz9 C mutants are C-terminally
Myc-tagged. Rfz9 (wild type) and Rfz9 N are not tagged unless
indicated as Rfz9-Myc and Rfz9 N-Myc (or N-Myc), respectively. As
shown in B, cells were transfected with 1 µg of Rfz9-Myc,
Rfz9 C ( C5, C15, C26, or C38), Rfz9 N-Myc, or vector,
and the proteins were detected with anti-Myc and anti-actin antibodies.
TM, transmembrane.
|
|

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 4.
Most of the Rfz9 C-terminal tails are
dispensable for Dvl-1 relocalization and hyperphosphorylation, and the
Rfz9 CRD is not required for Dvl-1 relocalization. Rfz9 deletion
mutants can relocalize Dvl-1 (A). Dvl-1-GFP was transfected
with vector (a-c), Rfz9-Myc (d-f), Rfz9 C38
(g-i), or Rfz9 N (j-l) into the cells.
Full-length Rfz9 and deletion mutants were detected with anti-Myc
antibody (d, g, and j); no Myc-tagged
protein was detected in vector-transfected cells (a).
Dvl-1-GFP was detected directly by fluorescence (b,
e, h, and k). Merged images
c, f, i, and l are from
images a and b, d and e,
g and h, and j and k,
respectively. Rfz9 C mutants can hyperphosphorylate Dvl-1
(B). Upper panel, Dvl-1-V5 (0.3 µg) was
cotransfected with 0.3 of µg of Rfz9 wild type, Rfz9 C ( C5,
C15, C26, or C38), or vector and 0.4 µg of vector to make up
a total of 1.0 µg of DNA. The proteins were detected with anti-V5
antibody. Lower panel, Dvl-1-V5 (0.3 µg) was cotransfected
with 0.7 µg of Rfz9 wild type, Rfz9 C ( C5, C15, C26, or
C38), or vector, and the proteins were detected with anti-V5
antibody.
|
|
When Dvl-1-GFP was coexpressed with each of the Rfz9 C constructs,
Dvl-1-GFP was relocalized to the plasma membrane, which is similar to
the effect of the wild-type Rfz9 (Fig. 4A, g-i, for Rfz9 C38 as the representation). Deletion of 38 amino acids, which is more than half of the C-terminal tail, did not affect the
ability of the receptor to relocalize Dvl-1-GFP, suggesting that most
of the Rfz9 C-terminal tail is dispensable for Dvl-1 relocalization. In some cells, which showed apparent low levels of Rfz9
wild-type or mutant expression, Dvl-1-GFP tended to show the membrane
localization, suggesting that Dvl-1 relocalization does not require
high levels of Rfz9 expression (Fig. 4A, d-f). Deletion of more than 38 amino acids resulted in poor protein expression (data not shown), preventing evaluation of their effect on
Dvl-1 localization.
The C-terminal tail deletions were also examined for their effect on
Dvl-1 hyperphosphorylation. Coexpression of Dvl-1-V5 with each of the
Rfz9 C mutants showed that they have the same effect on Dvl-1-V5 as
the wild-type Rfz9 (Fig. 4B). Cotransfection of 0.3 µg of
each Rfz9 mutant resulted in the disappearance of the lower band (Fig.
4B, upper panel), whereas 0.7 µg of a mutant transfection caused a third band to appear as the highest molecular weight (Fig. 4B, lower panel). These results
suggest that all Rfz9 C mutants were equally effective at inducing
Dvl-1-V5 phosphorylation as the wild-type Rfz9 and that most of the
Rfz9 C-terminal tail is not required for Dvl-1 hyperphosphorylation.
Most of the Rfz9 C-terminal Tail Is Required for -Catenin
Stabilization and TCF Transactivation--
The -catenin
stabilization and luciferase assay experiments were conducted to
compare Rfz9 wild-type and the C-terminal deletion mutants for their
ability to activate downstream targets. All the C mutants except
Rfz9 C5 failed to induce -catenin accumulation (Fig.
5A). These results are in
striking contrast to those of Dvl-1 relocalization and
hyperphosphorylation, suggesting that signal(s) in addition to Dvl-1
modifications are required for -catenin accumulation. The abilities
of the deletion mutants to induce TCF-dependent
transcription in the presence of Wnt-2 were also tested. Consistent
with the observed increase in cytosolic -catenin levels, only
Rfz9 C5 could increase TCF activity (Fig. 5B). Taken
together with the effects of the C-terminal tail deletions on Dvl-1
relocalization and hyperphosphorylation, these data suggest that there
is a difference in the Rfz9 C-terminal amino acids that are required
for the induction of the Dvl-1 modifications as compared with those
required for -catenin stabilization and TCF-dependent
transcription.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 5.
Most of the Rfz9 C-terminal tail are required
for -catenin accumulation and TCF
transcription. Rfz9 C mutants except C5 cannot accumulate
cytosolic -catenin (A). Cells were transfected with Rfz9
wild type, Rfz9 C ( C5, C15, C26, or C38), or vector.
Cytosol fractions were immunoblotted using anti- -catenin and
anti-actin antibodies. Rfz9 C mutants except C5 cannot activate
TCF transcription (B). Cells were transfected with 0.3 µg
of Rfz9 wild-type, Rfz9 C ( C5, C15, C26, or C38), or
vector, 0.6 µg of Wnt-2-HA or vector, 0.05 µg of TOPFLASH, and
0.05 µg of pcDNA3.1/LacZ. The relative values represent the
means from three independent experiments.
|
|
Rfz9 Deletion Mutant That Lacks the Extracellular Cysteine-rich
Domain Retains Activity--
In an attempt to further study the Wnt
dependence of Rfz9 activity, an N-terminal deletion mutant of Rfz9
(Rfz9 N) was generated that lacks a large part of the Rfz9 CRD. The
mutant was localized to the cell membrane. It not only retained the
ability to relocalize Dvl-1 (Fig. 4A, j-l), but
it also hyperphosphorylated Dvl-1 in a manner similar to the
wild-type and the C-terminal deletion mutants (Figs.
6A and 4B,
respectively). Moreover, Rfz9 N was able to accumulate -catenin to
a level similar to that of the wild type (Fig. 6B). In the
absence of Wnt-2, the TCF activity in the Rfz9 N-transfected cells
was similar to that in cells transfected with the wild type (Fig.
6C). Consistent with the lack of Wnt-binding domain, Wnt-2
coexpression had no effect on TCF activity induced by Rfz9 N (Fig.
6C). These results suggest that Rfz9 N maintains the
ability to activate downstream targets to a certain level but could not
be further activated by Wnt-2.

View larger version (27K):
[in this window]
[in a new window]
|
Fig. 6.
Rfz9 CRD is not required for Dvl-1
hyperphosphorylation, -catenin accumulation,
and TCF transcription but is required for Wnt-2-dependent
TCF transcription. Rfz9 N can hyperphosphorylate Dvl-1
(A). Upper panel, Dvl-1-V5 (0.3 µg) was
cotransfected with 0.3 µg of Rfz9 wild type, Rfz9 N, or vector and
0.4 µg of vector to make up a total of 1.0 µg of DNA. The proteins
were detected with anti-V5 antibody. Lower panel, Dvl-1-V5
(0.3 µg) was cotransfected with 0.7 µg of Rfz9 wild type, Rfz9 N,
or vector, and the proteins were detected with anti-V5 antibody.
Rfz9 N can accumulate cytosolic -catenin (B). Cells
were transfected with Rfz9 wild type, Rfz9 N, or vector. Cytosol
fractions were immunoblotted using anti- -catenin and anti-actin
antibodies. Rfz9 N can activate TCF transcription but cannot mediate
additional activation by Wnt-2 (C). Cells were transfected
with 0.3 µg of Rfz9 wild type, Rfz9 N, or vector, 0.6 µg of
Wnt-2-HA or vector, 0.05 µg of TOPFLASH, and 0.05 µg of
pcDNA3.1/LacZ. The relative values represent the means from three
independent experiments.
|
|
Axin Is Relocalized by Rfz9 in the Presence of Dvl-1--
Axin has
been known to be a negative regulator of Wnt/ -catenin signaling that
becomes relocalized from the cytoplasm to cell membrane by LRP5
overexpression. To determine whether Rfz9 is involved in this process,
a GFP fusion of Axin (Axin-GFP) was expressed in the cells together
with and without Rfz9-Myc. Rfz9-Myc overexpression had no effect on
Axin-GFP localization as it remained in the cytoplasm in a speckled
pattern similar to Dvl-1-GFP (Fig. 7A). It has been reported that
Dishevelled colocalizes with Axin in cells and that they directly
interact with each other (11, 41). It was possible that Dvl-1
relocalization by Rfz9 would also change Axin localization. Thus,
Dvl-1-V5 was coexpressed with Axin-GFP in the presence and absence of
Rfz9-Myc. Dvl-1-V5 localization shows the cytoplasmic speckled pattern
in the absence of Rfz9-Myc and the membrane-associated pattern in the
presence of Rfz9-Myc as expected (Fig. 7B, a and
d). Axin-GFP localization followed Dvl-1-V5 localization,
and in the presence of Rfz9-Myc, it was associated with the cell
membrane (Fig. 7B, a-f). Cotransfection of
Axin-GFP and Dvl-1-V5 with each of the Rfz9 C mutants or Rfz9 N resulted in the same membrane localization pattern of Axin-GFP (Fig.
7B, g-l, for Rfz9 C38 as the representation of
Rfz9 C mutants), suggesting that Axin relocalization is not dependent
on most of the Rfz9 C-terminal tail or the Wnt-binding domain. These
results also suggest that Axin relocalization is not sufficient to
activate Wnt/ -catenin signaling as Rfz9 C38, C26, and C15
relocalized Axin-GFP in the presence of Dvl-1-V5, but they did not
accumulate -catenin nor activate TCF activity as compared
with either wild type or Rfz9 C5 (Fig. 7B,
g-i, for Rfz9 C38 as the representation, and Fig. 5,
respectively).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 7.
Axin is relocalized by Rfz9 in the presence
of Dvl-1. Rfz9 alone does not affect Axin localization
(A). Axin-GFP was transfected with vector (a-c)
or Rfz9-Myc (d-f) into the cells. Rfz9-Myc was detected
with anti-Myc antibody (d), whereas no Myc-tagged protein
was detected in vector transfection (a). Axin-GFP was
detected directly by fluorescence (b and e).
Merged image c is from images a and b,
and merged image f is from images d and
e. Rfz9 relocalizes Axin in the presence of Dvl-1
(B). Axin-GFP and Dvl-1-V5 were cotransfected together with
vector (a-c), Rfz9-Myc (d-f), Rfz9 C38
(g-i), or Rfz9 N (j-l) into the cells.
Dvl-1-V5 was detected with anti-V5 antibody (a,
d, g, and j). Axin-GFP was detected
directly by fluorescence (b, e, h, and
k). Merged images c, f, i,
and l are from images a and b,
d and e, g and h, and
j and k, respectively.
|
|
 |
DISCUSSION |
Although there have been a number of studies on Wnt-Frizzled
interactions and signaling, most of them have involved
Drosophila genetics and Xenopus embryo studies.
Even the characterization of ligand binding and signaling properties of
mammalian Frizzled proteins has been carried out mostly with
Drosophila and Xenopus Wnt homologs, and many of
these studies have been conducted in Drosophila cell lines
or Xenopus embryos. Although these studies were helpful in
characterizing common protein structures and signaling mechanisms, they could neither address specificities of mammalian Wnt-Frizzled interactions nor effects of Frizzled activation in mammalian cells. In addition to the previous reports on Hfz1 and Mfz8
(27, 28), the present study on Rfz9 sheds new light on these issues and
uncovers a few novel aspects of the receptor function.
Previous studies on Hfz9 and Mfz9 have shown that Frizzled-9 is highly
expressed in the brain (29, 30). Although these studies did not show
that Frizzled-9 expression is brain-specific, we found that Rfz9
expression is highest in the
brain.2 It has also been
shown that Frizzled-9 is expressed in neural precursor cells in the
developing nervous system (42). Hfz9 was identified by searching genes
deleted in patients with Williams syndrome, a developmental
neurological disorder with deficits in visuospatial cognition (29).
Although it is still an open question whether Hfz9 is responsible for
some aspects of Williams syndrome pathology, its high expression in the
brain makes it likely to be involved in normal brain development.
Although Hfz9 has been shown to bind Drosophila Wg (29), it
was not known whether Frizzled-9 functions in Wnt/ -catenin
signaling. As a first step in characterizing Frizzled-9 functions, we
determined that Rfz9 activates Wnt/ -catenin signaling and can be
specifically activated by Wnt-2. Interestingly, a recent study
suggested that the WNT2 gene is an autism susceptibility
gene (43). The present study suggests that Wnt-2 is a possible
physiological ligand for Frizzled-9, although whether the functional
loss of either protein leads to developmental disorders in humans
remains to be determined.
With the deletion mutant analysis of Rfz9, we showed that most of the
C-terminal tail domain is not required for the induction of Dvl-1
hyperphosphorylation and relocalization. We also demonstrated that Rfz9
can relocalize Axin in the presence of Dvl-1. Although the Dishevelled
relocalization may have other roles, it is likely that Dishevelled acts
as a carrier protein that brings Axin to the plasma membrane, where
Axin is destabilized by LRP5/6 (7). The Axin relocalization and
destabilization might be required for inhibiting the negative
regulatory function of Axin, which leads to -catenin stabilization
and accumulation.
The cell fractionation and reporter gene assays demonstrated that most
of the Rfz9 C-terminal tail is necessary for the receptor-mediated accumulation of -catenin and activation of TCF transcription. This
finding is in contrast to a previous study on Xenopus
Frizzled-3 (Xfz3) in which the deletion of most of the C-terminal tail
did not compromise the expression of the -catenin responsive gene, Siamois (38). The C-terminal conserved motif
Lys-Thr-X-X-X-Trp was implicated in
mediating Wnt/ -catenin signaling (38). Although this motif may be
necessary for the Wnt/ -catenin signaling, whether or not it actually
mediates the signaling remains to be clarified since this motif is
conserved even among Frizzled members that have not been shown to
function in Wnt/ -catenin signaling. Thus, the motif may be only
required for maintaining proper receptor conformation. The apparent
discrepancy between Rfz9 and Xfz3 in functional requirements for the
presence of C-terminal tails could be explained by structural
differences between Rfz9 and Xfz3. Importantly, whereas the study on
Xfz3 did not find a difference in the requirements for the inductions
of the Dishevelled modifications and those of -catenin stabilization
and TCF transactivation, the present study determined that there is
such a difference in Rfz9. Additional studies are necessary to
determine whether this difference is also found with other Frizzled
members. Since Axin relocalization by Rfz9 and Dvl-1 is not dependent
on most of Rfz9 C-terminal tail, it is likely that Axin relocalization
is not sufficient to accumulate -catenin. The Axin
destabilization mediated by LRP5/6 may be required for the
-catenin accumulation, and it is possible that this process also
requires most of the Rfz9 C-terminal tail. Although we did not observe
any Axin destabilization by Rfz9 overexpression or coexpression of Rfz9
with Wnt-2 and/or Dvl-1, it could be because endogenous LRP5/6 activity
was not high enough to induce detectable levels of the Axin destabilization.
In this study, we also discovered that, even in the absence of the
Wnt-binding domain, Rfz9 N not only relocalizes and
hyperphosphorylates Dvl-1 but can also induce the accumulation of
cytosolic -catenin and activate TCF transcription. The fact that it
cannot be further activated by Wnt-2 is explained by the lack of the
Wnt-binding domain. Whether or not Dishevelled relocalization and
hyperphosphorylation induced by Frizzled are dependent on Wnt activity
remains unclear, although there have been some indications that Wnt
activity is responsible for these Dishevelled modifications (9, 36,
44). It is possible that there is some endogenous Wnt that can bind and
activate Rfz9 in these cells, and the deletion in Rfz9 N leads to a
conformation that is similar to activated wild-type Rfz9, thus inducing
the same effect on Dvl-1. This active conformation could also be
responsible for the cytosolic -catenin accumulation and TCF
transactivation by Rfz9 N. Another possibility is that Rfz9
isomerizes between two different states, an inactive and an active
conformation even in the absence of Wnt. Although the equilibrium
between the inactive and active states lies toward the inactive state,
overexpression of Rfz9 could cause the absolute amount of Rfz9 protein
in the active conformation to increase to the point at which basal
signaling can be detected. The deletion in Rfz9 N could adopt a
conformation that shifts the equilibrium toward the active state. The
finding that Rfz9 N acts as a weak constitutively active mutant could
be explained by an inability to interact with LRP5/6 through Wnt,
making the Axin destabilization mechanism inefficient. An important
function of Wnt may be to bring Frizzled and LRP5/6 together so that
-catenin becomes sufficiently accumulated, thereby inducing
TCF-dependent transcription required for the cellular activities.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Daniel J. Sussman for the Dvl-1
cDNA, Dr. Frank Costantini for the Axin cDNA, and Dr. Go
Watanabe for the TOPFLASH and FOPFLASH plasmids. We also thank Drs.
William C. Horne, David S. Russell, and Martin A. Julius for critical
reading of the manuscript and Drs. Christopher C. Quinn and Akihiko
Komuro for helpful discussions.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EBI Data Bank with accession number(s) AF455054.
To whom correspondence should be addressed: Child Study
Center, SHM I-270, Yale University School of Medicine, 230 South
Frontage Rd., New Haven, CT 06520. Tel.: 203-737-2224; Fax:
203-785-7611; E-mail: paul.lombroso@yale.edu.
Published, JBC Papers in Press, July 22, 2002, DOI 10.1074/jbc.M205658200
2
T. Karasawa, H. Yokokura, and P. J. Lombroso, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
LRP5/6, low
density lipoprotein-related proteins 5 and 6;
Rfz9, rat Frizzled-9;
Dvl-1, mouse Dishevelled-1;
Xdsh, Xenopus Dishevelled;
Hfz5, human Frizzled-5;
Hfz1, human Frizzled-1;
Mfz8, mouse Frizzled-8;
Wg, Wingless;
Xwnt-8, Xenopus Wnt-8;
Hfz9, human Frizzled-9;
Mfz9, mouse Frizzled-9;
Ddsh, Drosophila Dishevelled;
TCF, T
cell factor;
CRD, cysteine-rich domain;
GFP, green fluorescent protein;
PBS, phosphate-buffered saline;
HA, hemagglutinin.
 |
REFERENCES |
| 1.
|
Cadigan, K. M.,
and Nusse, R.
(1997)
Genes Dev.
11,
3286-3305[Free Full Text]
|
| 2.
|
Wodarz, A.,
and Nusse, R.
(1998)
Annu. Rev. Cell Dev. Biol.
14,
59-88[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Bhanot, P.,
Brink, M.,
Samos, C. H.,
Hsieh, J. C.,
Wang, Y.,
Macke, J. P.,
Andrew, D.,
Nathans, J.,
and Nusse, R.
(1996)
Nature
382,
225-230[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Hart, M. J.,
de los Santos, R.,
Albert, I. N.,
Rubinfeld, B.,
and Polakis, P.
(1998)
Curr. Biol.
8,
573-581[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Kishida, S.,
Yamamoto, H.,
Ikeda, S.,
Kishida, M.,
Sakamoto, I.,
Koyama, S.,
and Kikuchi, A.
(1998)
J. Biol. Chem.
273,
10823-10826[Abstract/Free Full Text]
|
| 6.
|
Tamai, K.,
Semenov, M.,
Kato, Y.,
Spokony, R.,
Liu, C.,
Katsuyama, Y.,
Hess, F.,
Saint-Jeannet, J. P.,
and He, X.
(2000)
Nature
407,
530-535[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Mao, J.,
Wang, J.,
Liu, B.,
Pan, W.,
Farr, G. H., 3rd,
Flynn, C.,
Yuan, H.,
Takada, S.,
Kimelman, D., Li, L.,
and Wu, D.
(2001)
Mol. Cell
7,
801-809[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Axelrod, J. D.,
Miller, J. R.,
Shulman, J. M.,
Moon, R. T.,
and Perrimon, N.
(1998)
Genes Dev.
12,
2610-2622[Abstract/Free Full Text]
|
| 9.
|
Yanagawa, S.,
van Leeuwen, F.,
Wodarz, A.,
Klingensmith, J.,
and Nusse, R.
(1995)
Genes Dev.
9,
1087-1097[Abstract/Free Full Text]
|
| 10.
|
Kishida, S.,
Yamamoto, H.,
Hino, S.,
Ikeda, S.,
Kishida, M.,
and Kikuchi, A.
(1999)
Mol. Cell. Biol.
19,
4414-4422[Abstract/Free Full Text]
|
| 11.
|
Smalley, M. J.,
Sara, E.,
Paterson, H.,
Naylor, S.,
Cook, D.,
Jayatilake, H.,
Fryer, L. G.,
Hutchinson, L.,
Fry, M. J.,
and Dale, T. C.
(1999)
EMBO J.
18,
2823-2835[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Ikeda, S.,
Kishida, S.,
Yamamoto, H.,
Murai, H.,
Koyama, S.,
and Kikuchi, A.
(1998)
EMBO J.
17,
1371-1384[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Sakanaka, C.,
Weiss, J. B.,
and Williams, L. T.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
3020-3023[Abstract/Free Full Text]
|
| 14.
|
Nakamura, T.,
Hamada, F.,
Ishidate, T.,
Anai, K.,
Kawahara, K.,
Toyoshima, K.,
and Akiyama, T.
(1998)
Genes Cells
3,
395-403[Abstract]
|
| 15.
|
Hedgepeth, C. M.,
Deardorff, M. A.,
Rankin, K.,
and Klein, P. S.
(1999)
Mol. Cell. Biol.
19,
7147-7157[Abstract/Free Full Text]
|
| 16.
|
Molenaar, M.,
van de Wetering, M.,
Oosterwegel, M.,
Peterson-Maduro, J.,
Godsave, S.,
Korinek, V.,
Roose, J.,
Destree, O.,
and Clevers, H.
(1996)
Cell
86,
391-399[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Korinek, V.,
Barker, N.,
Willert, K.,
Molenaar, M.,
Roose, J.,
Wagenaar, G.,
Markman, M.,
Lamers, W.,
Destree, O.,
and Clevers, H.
(1998)
Mol. Cell. Biol.
18,
1248-1256[Abstract/Free Full Text]
|
| 18.
|
Brannon, M.,
Gomperts, M.,
Sumoy, L.,
Moon, R. T.,
and Kimelman, D.
(1997)
Genes Dev.
11,
2359-2370[Abstract/Free Full Text]
|
| 19.
|
Tetsu, O.,
and McCormick, F.
(1999)
Nature
398,
422-426[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
He, T. C.,
Sparks, A. B.,
Rago, C.,
Hermeking, H.,
Zawel, L.,
da Costa, L. T.,
Morin, P. J.,
Vogelstein, B.,
and Kinzler, K. W.
(1998)
Science
281,
1509-1512[Abstract/Free Full Text]
|
| 21.
|
Tao, W.,
Pennica, D., Xu, L.,
Kalejta, R. F.,
and Levine, A. J.
(2001)
Genes Dev.
15,
1796-1807[Abstract/Free Full Text]
|
| 22.
|
Hsieh, J. C.,
Rattner, A.,
Smallwood, P. M.,
and Nathans, J.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
3546-3551[Abstract/Free Full Text]
|
| 23.
|
Dann, C. E.,
Hsieh, J. C.,
Rattner, A.,
Sharma, D.,
Nathans, J.,
and Leahy, D. J.
(2001)
Nature
412,
86-90[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Wang, Y.,
Macke, J. P.,
Abella, B. S.,
Andreasson, K.,
Worley, P.,
Gilbert, D. J.,
Copeland, N. G.,
Jenkins, N. A.,
and Nathans, J.
(1996)
J. Biol. Chem.
271,
4468-4476[Abstract/Free Full Text]
|
| 25.
|
Yang-Snyder, J.,
Miller, J. R.,
Brown, J. D.,
Lai, C. J.,
and Moon, R. T.
(1996)
Curr. Biol.
6,
1302-1306[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
He, X.,
Saint-Jeannet, J. P.,
Wang, Y.,
Nathans, J.,
Dawid, I.,
and Varmus, H.
(1997)
Science
275,
1652-1654[Abstract/Free Full Text]
|
| 27.
|
Gazit, A.,
Yaniv, A.,
Bafico, A.,
Pramila, T.,
Igarashi, M.,
Kitajewski, J.,
and Aaronson, S. A.
(1999)
Oncogene
18,
5959-5966[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Wu, W.,
Glinka, A.,
Delius, H.,
and Niehrs, C.
(2000)
Curr. Biol.
10,
1611-1614[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Wang, Y. K.,
Samos, C. H.,
Peoples, R.,
Perez-Jurado, L. A.,
Nusse, R.,
and Francke, U.
(1997)
Hum. Mol. Genet.
6,
465-472[Abstract/Free Full Text]
|
| 30.
|
Wang, Y. K.,
Sporle, R.,
Paperna, T.,
Schughart, K.,
and Francke, U.
(1999)
Genomics
57,
235-248[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Moriguchi, T.,
Kawachi, K.,
Kamakura, S.,
Masuyama, N.,
Yamanaka, H.,
Matsumoto, K.,
Kikuchi, A.,
and Nishida, E.
(1999)
J. Biol. Chem.
274,
30957-30962[Abstract/Free Full Text]
|
| 32.
|
Shimizu, H.,
Julius, M. A.,
Giarre, M.,
Zheng, Z.,
Brown, A. M.,
and Kitajewski, J.
(1997)
Cell Growth & Differ.
8,
1349-1358[Abstract]
|
| 33.
|
Korinek, V.,
Barker, N.,
Morin, P. J.,
van Wichen, D.,
de Weger, R.,
Kinzler, K. W.,
Vogelstein, B.,
and Clevers, H.
(1997)
Science
275,
1784-1787[Abstract/Free Full Text]
|
| 34.
|
Kuhl, M.,
Sheldahl, L. C.,
Park, M.,
Miller, J. R.,
and Moon, R. T.
(2000)
Trends Genet.
16,
279-283[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Rothbacher, U.,
Laurent, M. N.,
Deardorff, M. A.,
Klein, P. S.,
Cho, K. W.,
and Fraser, S. E.
(2000)
EMBO J.
19,
1010-1022[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Lee, J. S.,
Ishimoto, A.,
and Yanagawa, S.
(1999)
J. Biol. Chem.
274,
21464-21470[Abstract/Free Full Text]
|
| 37.
|
Sheldahl, L. C.,
Park, M.,
Malbon, C. C.,
and Moon, R. T.
(1999)
Curr. Biol.
9,
695-698[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Umbhauer, M.,
Djiane, A.,
Goisset, C.,
Penzo-Mendez, A.,
Riou, J. F.,
Boucaut, J. C.,
and Shi, D. L.
(2000)
EMBO J.
19,
4944-4954[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Sakamoto, I.,
Kishida, S.,
Fukui, A.,
Kishida, M.,
Yamamoto, H.,
Hino, S.,
Michiue, T.,
Takada, S.,
Asashima, M.,
and Kikuchi, A.
(2000)
J. Biol. Chem.
275,
32871-32878[Abstract/Free Full Text]
|
| 40.
|
Tago, K.,
Nakamura, T.,
Nishita, M.,
Hyodo, J.,
Nagai, S.,
Murata, Y.,
Adachi, S.,
Ohwada, S.,
Morishita, Y.,
Shibuya, H.,
and Akiyama, T.
(2000)
Genes Dev.
14,
1741-1749[Abstract/Free Full Text]
|
| 41.
|
Fagotto, F.,
Jho, E.,
Zeng, L.,
Kurth, T.,
Joos, T.,
Kaufmann, C.,
and Costantini, F.
(1999)
J. Cell Biol.
145,
741-756[Abstract/Free Full Text]
|
| 42.
|
Van Raay, T. J.,
Wang, Y. K.,
Stark, M. R.,
Rasmussen, J. T.,
Francke, U.,
Vetter, M. L.,
and Rao, M. S.
(2001)
Dev. Genes Evol.
211,
453-457[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Wassink, T. H.,
Piven, J.,
Vieland, V. J.,
Huang, J.,
Swiderski, R. E.,
Pietila, J.,
Braun, T.,
Beck, G.,
Folstein, S. E.,
Haines, J. L.,
and Sheffield, V. C.
(2001)
Am. J. Med. Genet.
105,
406-413[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Steitz, S. A.,
Tsang, M.,
and Sussman, D. J.
(1996)
In Vitro Cell. Dev. Biol. Anim.
32,
441-445[Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. Carraro, S. Ferraresso, B. Cardazzo, C. Romualdi, C. Montesissa, F. Gottardo, T. Patarnello, M. Castagnaro, and L. Bargelloni
Expression profiling of skeletal muscle in young bulls treated with steroidal growth promoters
Physiol Genomics,
July 1, 2009;
38(2):
138 - 148.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Jiang, A. Dunbar, L. P. Gondek, S. Mohan, M. Rataul, C. O'Keefe, M. Sekeres, Y. Saunthararajah, and J. P. Maciejewski
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
Blood,
February 5, 2009;
113(6):
1315 - 1325.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-X. Wang, F. R. Tekpetey, and G. M. Kidder
Identification of WNT/{beta}-CATENIN signaling pathway components in human cumulus cells
Mol. Hum. Reprod.,
January 1, 2009;
15(1):
11 - 17.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. D. Armstrong and K. A. Esser
Wnt/{beta}-catenin signaling activates growth-control genes during overload-induced skeletal muscle hypertrophy
Am J Physiol Cell Physiol,
October 1, 2005;
289(4):
C853 - C859.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Zhao, C. Aviles, R. A. Abel, C. R. Almli, P. McQuillen, and S. J. Pleasure
Hippocampal and visuospatial learning defects in mice with a deletion of frizzled 9, a gene in the Williams syndrome deletion interval
Development,
June 15, 2005;
132(12):
2917 - 2927.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Winn, L. Marek, S.-Y. Han, K. Rodriguez, N. Rodriguez, M. Hammond, M. Van Scoyk, H. Acosta, J. Mirus, N. Barry, et al.
Restoration of Wnt-7a Expression Reverses Non-small Cell Lung Cancer Cellular Transformation through Frizzled-9-mediated Growth Inhibition and Promotion of Cell Differentiation
J. Biol. Chem.,
May 20, 2005;
280(20):
19625 - 19634.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Fahnert, J. Veijola, G. Roel, M. K. Karkkainen, A. Railo, O. Destree, S. Vainio, and P. Neubauer
Murine Wnt-1 with an Internal c-myc Tag Recombinantly Produced in Escherichia coli Can Induce Intracellular Signaling of the Canonical Wnt Pathway in Eukaryotic Cells
J. Biol. Chem.,
November 12, 2004;
279(46):
47520 - 47527.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Gonzalez-Sancho, K. R. Brennan, L. A. Castelo-Soccio, and A. M. C. Brown
Wnt Proteins Induce Dishevelled Phosphorylation via an LRP5/6- Independent Mechanism, Irrespective of Their Ability To Stabilize {beta}-Catenin
Mol. Cell. Biol.,
June 1, 2004;
24(11):
4757 - 4768.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Caricasole, T. Ferraro, L. Iacovelli, E. Barletta, A. Caruso, D. Melchiorri, G. C. Terstappen, and F. Nicoletti
Functional Characterization of WNT7A Signaling in PC12 Cells: INTERACTION WITH A FZD5{middle dot}LRP6 RECEPTOR COMPLEX AND MODULATION BY DICKKOPF PROTEINS
J. Biol. Chem.,
September 26, 2003;
278(39):
37024 - 37031.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|